Retrospective study assessing outcomes in cardiac surgery after implementation of Quantra.
Blood management
Cardiac surgery
Point-of-care testing, Quantra, Transfusion
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
17 Apr 2023
17 Apr 2023
Historique:
received:
26
08
2022
accepted:
02
04
2023
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
epublish
Résumé
The Quantra QPlus System is a cartridge-based device with a unique ultrasound technology that can measure the viscoelastic properties of whole blood during coagulation. These viscoelastic properties correlate directly with hemostatic function. The primary objective of this study was to assess blood product utilization in cardiac surgery patients before and after the implementation of the Quantra QPlus System. Yavapai Regional Medical Center implemented the Quantra QPlus System to aid in their efforts to reduce the transfusion of allogenic blood products and improve outcomes in patients undergoing cardiac surgery. A total of 64 patients were enrolled prior to the utilization of the Quantra (pre-Quantra cohort), and 64 patients were enrolled after (post-Quantra cohort). The pre-Quantra cohort had been managed via standard laboratory assays along with physician discretion for transfusion decisions. The utilization of blood products and frequency of transfusions were compared and analyzed between the two cohorts. (using the Student's t-test) RESULTS: The implementation of the Quantra resulted in a change in the pattern of blood product utilization leading to a demonstrated decrease in the amount of blood products transfused and the associated costs. The amount of FFP transfused was significantly decreased by 97% (P = 0.0004), whereas cryoprecipitate decreased by 67% (P = 0.3134), platelets decreased by 26% (P = 0.4879), and packed red blood cells decreased by 10% (P = 0.8027) however these trends did not reach statistical significance. The acquisition cost of blood products decreased by 41% for total savings of roughly $40,682. Use of the Quantra QPlus System has the potential to improve patient blood management and decrease costs. STUDY REGISTERED AT CLINICALTRIALS.GOV: NCT05501730.
Sections du résumé
BACKGROUND
BACKGROUND
The Quantra QPlus System is a cartridge-based device with a unique ultrasound technology that can measure the viscoelastic properties of whole blood during coagulation. These viscoelastic properties correlate directly with hemostatic function. The primary objective of this study was to assess blood product utilization in cardiac surgery patients before and after the implementation of the Quantra QPlus System.
METHODS
METHODS
Yavapai Regional Medical Center implemented the Quantra QPlus System to aid in their efforts to reduce the transfusion of allogenic blood products and improve outcomes in patients undergoing cardiac surgery. A total of 64 patients were enrolled prior to the utilization of the Quantra (pre-Quantra cohort), and 64 patients were enrolled after (post-Quantra cohort). The pre-Quantra cohort had been managed via standard laboratory assays along with physician discretion for transfusion decisions. The utilization of blood products and frequency of transfusions were compared and analyzed between the two cohorts. (using the Student's t-test) RESULTS: The implementation of the Quantra resulted in a change in the pattern of blood product utilization leading to a demonstrated decrease in the amount of blood products transfused and the associated costs. The amount of FFP transfused was significantly decreased by 97% (P = 0.0004), whereas cryoprecipitate decreased by 67% (P = 0.3134), platelets decreased by 26% (P = 0.4879), and packed red blood cells decreased by 10% (P = 0.8027) however these trends did not reach statistical significance. The acquisition cost of blood products decreased by 41% for total savings of roughly $40,682.
CONCLUSIONS
CONCLUSIONS
Use of the Quantra QPlus System has the potential to improve patient blood management and decrease costs. STUDY REGISTERED AT CLINICALTRIALS.GOV: NCT05501730.
Identifiants
pubmed: 37069685
doi: 10.1186/s13019-023-02245-x
pii: 10.1186/s13019-023-02245-x
pmc: PMC10109219
doi:
Banques de données
ClinicalTrials.gov
['NCT05501730']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149Informations de copyright
© 2023. The Author(s).
Références
Minerva Anestesiol. 2007 Jul-Aug;73(7-8):401-15
pubmed: 17380100
Br J Haematol. 2018 Sep;182(6):789-806
pubmed: 30073664
Ann Biomed Eng. 2016 May;44(5):1405-24
pubmed: 26399992
J Cardiothorac Vasc Anesth. 2021 Sep;35(9):2569-2591
pubmed: 34217578
Eur J Cardiothorac Surg. 2018 Jan 1;53(1):79-111
pubmed: 29029100
Anesth Analg. 2016 Dec;123(6):1372-1379
pubmed: 27224934
J Cardiothorac Vasc Anesth. 2019 Jun;33(6):1590-1598
pubmed: 30737122
Circulation. 2007 Nov 27;116(22):2544-52
pubmed: 17998460
J Cardiothorac Vasc Anesth. 2019 Nov;33(11):2887-2899
pubmed: 31604540
Anesthesiology. 2012 Sep;117(3):531-47
pubmed: 22914710
Vox Sang. 2015 Oct;109(3):267-79
pubmed: 25930098
Circulation. 2016 Oct 18;134(16):1152-1162
pubmed: 27654344
Anesth Analg. 2016 Dec;123(6):1400-1407
pubmed: 27159065
J Cardiothorac Vasc Anesth. 2019 Apr;33(4):976-984
pubmed: 30279065
Clin Appl Thromb Hemost. 2017 Apr;23(3):201-210
pubmed: 26400661
Anesth Analg. 2016 Dec;123(6):1380-1389
pubmed: 27584686
Anesth Analg. 2016 Dec;123(6):1390-1399
pubmed: 27749339
Clin Ther. 2015 Sep 1;37(9):1966-74
pubmed: 26210074
Anesthesiology. 2015 Feb;122(2):241-75
pubmed: 25545654
Transfusion. 2008 Mar;48(1 Suppl):2S-30S
pubmed: 18302579